Abstract:OBJECTIVE:To assess the efficacy and pathological change of fertility-sparing treatment with progestin for endometrial carcinoma (EC) of stage I a and complex atypical hyperplasia (CAH) and to observe the prognosis of the treatment.METHODS:Nine EC patients of stage I a and 21 CAH patients aged under 40 years who desired childbearing and retaining their fertility were enrolled into this study. All patients were given a daily oral high-dose of progestin with duration of treatment ranging from 6 to 9 months. Diagnostic curettage was performed every 3 months as a modality for seeing the histologic change of neoplastic tissues and endometrial tissue. A careful and long- term follow- up is necessary for patients with complete response (CR).RESULTS:During the first period of fertility-sparing management, according to histologic change, 5 EC patients and 18 CAH patients showed CR with no evidence of endometrial adenocarcinoma or hyperplasia, 2 EC patients and 2 CAH patients showed partial response with a regression to complex or simple hyperplasia without atypia, 2 EC patients and 1 CAH patient showed stable disease or progressive disease. Accordingly, a total of 26 patients showed CR (26 of 30 patients). The median time to CR was 6 months (range, 3 to 21 months) of progestin treatment. The median follow-up time was 55.5 months (range, 24 to 104 months) and all patients were alive. During follow-up, among the 26 patients with CR, 3 of 6 EC patients achieved CR recurred disease after a median time interval of 10 months (range, 6 to 51 months), 7 of 20 CAH patients achieved CR had recurrent disease after a median time interval of 12 months (range, 6 to 55 months). Four of 7 CAH with recurrent disease achieved CR to progestin re-treatment. Eight of 26 patients achieved CR continued a further 3 or 6 months of consolidation therapy, 3 of them had recurrent disease, the remaining 18 stopped progesterone treatment after CR and 7 patients had recurrent disease; there was no significant statistical difference between the two groups (P = 1.000). EC patients succeeded in 4 pregnancies, CAH patients succeeded in 10 pregnancies, they gave birth to 16 healthy babies in all.CONCLUSIONS:EC of stage I a and CAH had slow progression of symptoms. Progestin treatment in EC of stage I a and CAH patients was effective. A careful and long-term follow-up is required because of the substantial high rate of recurrence. Progestin re-treatment in most patients with recurrent endometrial cancer is effective and safe.

[Clinical Analysis of Fertility-Sparing Therapy of Patients with Complex Atypical Hyperplasia and Endometrial Cancer].

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

Fertility-preserving Treatment and Pregnancy Outcomes in the Early Stage of Endometrial Carcinoma.

[Analysis of Pregnancy Outcome after Fertility-Preserving Treatment among Women with Atypical Endometrial Hyperplasia or Endometrial Carcinoma].

Outcome of Conservative Treatment and Subsequent Assisted Reproductive Technology for Patients with Early-Stage Endometrial Adenocarcinoma and Poor Fertility Potential

[Analysis of Prognosis and Pregnancy Outcomes of Fertility-Preserving Treatment for Patients with Stage Ⅰa, Grade 2 Endometrial Cancer].

Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy

Use of Clinicopathological Factors to Predict Prognosis of Fertility-Sparing Treatment for Endometrial Endometrioid Carcinoma and Atypical Hyperplasia

Analysis of Pregnancy-Associated Factors after Fertility-Sparing Therapy in Young Women with Early Stage Endometrial Cancer or Atypical Endometrial Hyperplasia

Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity

EP657 the Risk Factors and Therapeutic Regimens Analyses in the Fertility-Sparing Treatment of Refractory Endometrial Atypical Hyperplasia and Endometrial Cancer

Clinical Features and Outcome of 15 Patients with Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Received Primary Fertility-Sparing Therapy Followed by Hysterectomy

Prognostic Factors of Oncological and Reproductive Outcomes in Fertility-Sparing Treatment of Complex Atypical Hyperplasia and Low-Grade Endometrial Cancer Using Oral Progestin in Chinese Patients

Fertility-preserving Treatment Outcome in Endometrial Cancer or Atypical Hyperplasia Patients with Polycystic Ovary Syndrome.

Analysis of Immunohistochemical Characteristics and Recurrence after Complete Remission with Fertility Preservation Treatment in Patients with Endometrial Carcinoma and Endometrial a Typical Hyperplasia

Significance of Serum and Pathological Biomarkers in Fertility-Sparing Treatment for Endometrial Cancer or Atypical Hyperplasia: a Retrospective Cohort Study

Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia.

Impact Of Treatment Duration In Fertility-Preserving Management Of Endometrial Cancer Or Atypical Endometrial Hyperplasia

Maintenance Therapy Can Improve the Oncologic Prognosis and Obstetrical Outcome of Patients with Atypical Endometrial Hyperplasia and Endometrial Cancer after Fertility-Preserving Treatment: A Multicenter Retrospective Study

Clinicopathological Analysis Of Fertility-Sparing Treatment And Pregnancy Outcomes In Young Women With Early-Stage Endometrial Carcinoma

Analysis of the Clinical Outcome of in Vitro Fertilization in Infertility Patients with Conservative Treatment of Atypical Endometrial Hyperplasia and Early Well-Differentiated Endometrial Adenocarcinoma